AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
39.98
+0.31 (+0.78%)
At close: 4:00PM EDT

40.67 +0.69 (1.73%)
Pre-Market: 9:03AM EDT

Stock chart is not supported by your current browser
Previous Close39.67
Open39.56
Bid40.62 x 1300
Ask40.65 x 1800
Day's Range39.55 - 40.13
52 Week Range34.38 - 43.30
Volume1,788,762
Avg. Volume4,750,701
Market Cap107.166B
Beta (3Y Monthly)0.45
PE Ratio (TTM)42.08
EPS (TTM)0.95
Earnings DateN/A
Forward Dividend & Yield1.40 (3.75%)
Ex-Dividend Date2019-02-28
1y Target Est45.10
Trade prices are not sourced from all markets
  • How AstraZeneca Is Advancing Its Oncology Portfolio in 2019
    Market Realist16 minutes ago

    How AstraZeneca Is Advancing Its Oncology Portfolio in 2019

    On March 28, AstraZeneca (AZN) issued a press release announcing its collaboration with Daiichi Sankyo for the development and commercialization of trastuzumab deruxtecan, an investigational therapy currently being evaluated for multiple HER2-expressing cancers.

  • AstraZeneca’s Lynparza Continues to Dominate
    Market Realist2 hours ago

    AstraZeneca’s Lynparza Continues to Dominate

    In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan.

  • AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
    Reuters6 hours ago

    AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

    Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co , can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said. BRCA genes are responsible for producing proteins which repair damaged DNA, and if the genes are mutated, they can cause cancer growth.

  • Reuters6 hours ago

    UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

    British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April. Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co, can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said.

  • Tagrisso: AstraZeneca’s Top-Selling Drug in Q1
    Market Realist17 hours ago

    Tagrisso: AstraZeneca’s Top-Selling Drug in Q1

    AstraZeneca's (AZN) Tagrisso was approved by the FDA first for the treatment of epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer and then as a first-line therapy for EGFR-mutated NSCLC. The drug has become the highest-selling drug in AstraZeneca’s portfolio.

  • How Are AstraZeneca’s Revenues Trending in 2019?
    Market Realist18 hours ago

    How Are AstraZeneca’s Revenues Trending in 2019?

    On its first-quarter earnings conference call, AstraZeneca (AZN) guided for year-over-year product sales growth in high-single-digit percentage in 2019. The company, however, expects modest product sales growth in the second half of 2019 due to higher oncology revenue in the previous period.

  • What Analysts Recommend for Merck and AstraZeneca in June
    Market Realist20 hours ago

    What Analysts Recommend for Merck and AstraZeneca in June

    Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.

  • AstraZeneca Gives Detailed Data From Calquence Leukemia Study
    Zacks23 hours ago

    AstraZeneca Gives Detailed Data From Calquence Leukemia Study

    AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.

  • CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Business Wire3 days ago

    CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia

    An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine

  • Is AstraZeneca plc  (AZN) A Good Stock To Buy?
    Insider Monkey4 days ago

    Is AstraZeneca plc (AZN) A Good Stock To Buy?

    At Insider Monkey we follow nearly 750 of the best-performing investors and even though many of them lost money in the last couple of months of 2018 (some actually delivered very strong returns), the history teaches us that over the long-run they still manage to beat the market, which is why it can be profitable […]

  • Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
    Zacks4 days ago

    Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

    Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

  • Business Wire4 days ago

    LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis

    In Phase IIIb DIALIZE trial, 41.2% of LOKELMA patients maintained normal potassium levels pre-dialysis compared to 1% receiving placebo

  • Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
    Zacks5 days ago

    Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock

    Here are five reasons why investors may consider betting on Merck (MRK) stock

  • The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
    Zacks8 days ago

    The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

    The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

  • Business Wire8 days ago

    FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes

    FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58

  • What Kind Of Shareholders Own AstraZeneca PLC (LON:AZN)?
    Simply Wall St.8 days ago

    What Kind Of Shareholders Own AstraZeneca PLC (LON:AZN)?

    A look at the shareholders of AstraZeneca PLC (LON:AZN) can tell us which group is most powerful. Institutions will...

  • New Sanofi CEO 2019: 8 Things to Know About Paul Hudson
    InvestorPlace11 days ago

    New Sanofi CEO 2019: 8 Things to Know About Paul Hudson

    There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring.Source: Shutterstock Here's what you need to know about Sanofi's (NASDAQ:SNY) new CEO. * The new Sanofi CEO is Paul Hudson. * He will be taking over the role of CEO from Brandicourt starting on Sept. 1, 2019. * Hudson's most recent work includes serving as the CEO of Novartis Pharmaceuticals (NYSE:NVS) and being a member on the Novartis Executive Committee. * The new Sanofi CEO also has plenty of experience working with pharmaceutical companies over the last 28 years. * Some of his major previous employers include Schering Plough, Astra Zeneca (NYSE:AZN) and Novartis. * This has given him plenty of experience working in the markets of the U.S., Japan and Europe. * It has also awarded him the experience needed to handle leadership through his previous management roles. * Paul Hudson will also be moving to Paris, France to serve in his role as CEO of the company, which has its headquarter there. * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% Serge Weinberg, Chairman of the Board of Directors for Sanofi, has this to say about the change.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are very pleased that Paul Hudson has agreed to join Sanofi. His skills and experience give him all the assets he needs to accelerate growth and lead the Group's adaptation to new strategic challenges, particularly in the areas of Research and Development and digital. His human values will enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world."SNY stock was up 5% as of Friday morning. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post New Sanofi CEO 2019: 8 Things to Know About Paul Hudson appeared first on InvestorPlace.

  • AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study
    Zacks11 days ago

    AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study

    AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.

  • Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
    Zacks11 days ago

    Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

    Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

  • Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
    Zacks12 days ago

    Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

    The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

  • Cancer-Fighting Stocks & ETF: What You Need to Know
    Zacks13 days ago

    Cancer-Fighting Stocks & ETF: What You Need to Know

    Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

  • Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
    Zacks13 days ago

    Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

    Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.

  • Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options
    Zacks13 days ago

    Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options

    GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.

  • How Merck reached new ground in the fight against cancer
    Yahoo Finance Video13 days ago

    How Merck reached new ground in the fight against cancer

    A major break through in the fight against lung cancer. Merck announced that its drug Keytruda has shown an increase in the survival for those suffering from lung cancer. Merck CFO Rob Davis talks with Yahoo Finance's Adam Shapiro and Julie Hyman.